retatrutide clinical trials status 2025 Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage trial, the company announced. In Retatrutide Promises Big Weight Loss,

Several studies have shown to reduce the overall body fat percentage, belly fat and blood triglycerides

But once food intake drops, nutritional density suddenly matters far more than before

Healthier on Ro

2025: Biocon strengthened its GLP-1 presence with two key milestones

The Ominous Octet: Multiple Pathophysiologic Defects in Type 2 Diabetes Mellitus (T2DM) 2 This review will focus on incretin-based therapies (DPP-4 inhibitors and GLP-1 receptor agonists) and SGLT-2 inhibitors currently approved for the treatment of T2DM

Unlike diets that rely on willpower, GLP-1 injections work with your bodys natural biology , making weight loss easier and more sustainable